Laboratory tests - urate

Role

Serum urate is central to the diagnosis and, particularly, the long-term management of gout - used both to support the diagnosis in the acute setting and, more importantly, as a treatment target for urate-lowering therapy
Gout is the most common inflammatory arthritis overall, and serum urate management (rather than acute flare treatment alone) is the key determinant of long-term disease control

Urate crystallises as monosodium urate when its solubility limit in serum/synovial fluid is exceeded (above ~0.36-0.42 mmol/L depending on the reference used), depositing in joints and soft tissue and triggering an acute inflammatory response when crystals are phagocytosed and activate the NLRP3 inflammasome

Serum urate can be normal or even low during an acute gout flare (urate is consumed/redistributed into the inflamed joint during the acute attack) - a normal urate level during an acute flare does NOT exclude gout, a frequently tested diagnostic trap
Joint aspiration with polarised light microscopy (showing negatively birefringent needle-shaped crystals) remains the definitive diagnostic test when available, rather than relying on serum urate alone

Urate-lowering therapy (allopurinol first-line, febuxostat as an alternative) is titrated to a target serum urate <0.36 mmol/L (lower, <0.30 mmol/L, in patients with tophaceous gout) - "treat to target" using serial urate measurement, analogous to treating hypertension to a BP target
Do NOT start urate-lowering therapy during an acute flare - it can prolong or worsen the acute attack by causing further crystal mobilisation; start once the acute flare has settled, with anti-inflammatory cover (colchicine or NSAID) during initiation to reduce flare risk from the urate-lowering therapy itself
Once started, urate-lowering therapy is generally continued lifelong, not stopped once urate normalises, since stopping typically leads to urate re-accumulation and flare recurrence

Tophaceous gout, urate nephropathy/renal stones, metabolic syndrome (commonly coexists with hyperuricaemia), pseudogout (the key crystal arthropathy differential, with calcium pyrophosphate rather than urate crystals)

The "normal urate during a flare" trap and the "don't start urate-lowering therapy during an acute attack" principle are two of the most frequently tested, clinically important points in gout management - both reflect the same underlying pharmacodynamic reality that urate mobilisation, not just its absolute level, drives acute flares

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.